Article Details

Harbour BioMed, AstraZeneca sign license deal for bispecific antibody

Retrieved on: 2022-04-08 11:48:15

Tags for this article:

Click the tags to see associated articles and topics

Harbour BioMed, AstraZeneca sign license deal for bispecific antibody. View article details on hiswai:

Excerpt

Harbour BioMed (HBM) and AstraZeneca have entered into a global out-license agreement for CLDN18.2xCD3 bispecific antibody HBM7022.

Article found on: www.pharmaceutical-business-review.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up